Medicare AdvantageCoverageMedium impact
MA11.004q, Surgical and Minimally Invasive Treatments for Urinary Outlet Obstruction due to Benign Prostatic Hyperplasia (BPH)
Independence Blue Cross·Urology·Medical Policy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
This policy (MA11.004q) addresses coverage and billing for surgical and minimally invasive treatments for benign prostatic hyperplasia (BPH)-related urinary outlet obstruction. The policy became effective 01/01/2026 and applies to Medicare Advantage plans. The billing team must review specific procedures, prior authorization requirements, and covered treatment modalities to ensure compliant claims submission.
Action Required
By 01/01/2026: Billing team must obtain and review the complete MA11.004q policy document at https://medpolicy.ibx.com/ibc/ma/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=01&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#medicare-advantage-ma11-004q-surgical-and-minimally-invasive to identify: (1) specific CPT/HCPCS codes covered for BPH surgical and minimally invasive treatments; (2) prior authorization requirements; (3) medical necessity criteria; (4) any exclusions or limitations. Update billing system rules, encounter forms, and provider documentation templates accordingly. Establish verification process with providers to ensure claims include required supporting documentation before submission. Failure to comply with coverage criteria will result in claim denials.